Literature DB >> 21870745

[Assessment tumor markers by immunohistochemistry (Ki67, p53 and Bcl-2) on a cohort of patients with cervical cancer in various stages of evolution].

T M Stoenescu1, Luminiţa Dana Ivan, Nicoleta Stoenescu, Doina Azoicăi.   

Abstract

In defining new potential prognostic factors in cervical cancer, p53 protein expression, Ki67 or issues related to Bcl-2 oncogene involved in cellular apoptosis process, have been the subject of numerous publications. This paper aims to study with immunohistochemical methods, the way in which these factors are involved in influencing the prognosis of patients with cervical cancer. The study was conducted on 42 pieces operators from the same number of patients diagnosed with this disease, aged between 25-65 years and in different clinical stages. We used an experimental design type 2 (histopathological type squamous cell/adenocarcinoma) x 3 (degree of differentiation weak/ moderate/ well differentiated) x 4 (stage I/ II/ III /IV disease). Diagnosis was based on clinical examination and confirmed by histopathology, and hypothesis testing we used Kruskal-Wallis ANOVA test of ranks test, Mann-Whitney U test, chi2 test, Spearman's correlation test and crosstabs ranking difference. The results on the study group showed the prognostic value of both the proliferation marker Ki67 and p53 oncogene, the presence of tandem Ki67/p53 in cervical carcinoma meaning more so a poor prognosis, Bcl-2 overexpression was detected in none of the 42 cases investigated.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21870745

Source DB:  PubMed          Journal:  Rev Med Chir Soc Med Nat Iasi        ISSN: 0048-7848


  3 in total

1.  MiR-125a suppresses tumor growth, invasion and metastasis in cervical cancer by targeting STAT3.

Authors:  Zhongyi Fan; Hanzhi Cui; Xiaojie Xu; Zhi Lin; Xuelin Zhang; Lei Kang; Baiyu Han; Jing Meng; Zhifeng Yan; Xiang Yan; Shunchang Jiao
Journal:  Oncotarget       Date:  2015-09-22

2.  SKA3 promotes cell proliferation and migration in cervical cancer by activating the PI3K/Akt signaling pathway.

Authors:  Rong Hu; Ming-Qing Wang; Wen-Bo Niu; Yan-Jing Wang; Yang-Yang Liu; Ling-Yu Liu; Ming Wang; Juan Zhong; Hai-Yan You; Xiao-Hui Wu; Ning Deng; Lu Lu; Lian-Bo Wei
Journal:  Cancer Cell Int       Date:  2018-11-14       Impact factor: 5.722

3.  Discovery and validation of novel biomarkers for detection of cervical cancer.

Authors:  Zigang Li; Jianhua Chen; Shaobo Zhao; Yajun Li; Jie Zhou; Jianghong Liang; Huifang Tang
Journal:  Cancer Med       Date:  2021-02-23       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.